De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate
出于安全考虑,对多发性硬化症患者进行疾病修饰疗法降级:对 25 例从奥克瑞珠单抗换用富马酸二甲酯治疗的患者进行 1 年疗效分析。
期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-02902-0
Gudesblatt, Mark; Bumstead, Barbara; Buhse, Marijean; Zarif, Myassar; Morrow, Sarah A; Nicholas, Jacqueline A; Hancock, Laura M; Wilken, Jeffrey; Weller, Joanna; Scott, Nicole; Gocke, Anne; Lewin, James B; Kaczmarek, Olivia; Mendoza, Jason P; Golan, Daniel